Background/purpose of the study
Little is known about all-cause liver disease in people with serious mental illness (SMI), despite heightened risk factors. We, therefore, prospectively assessed liver disease by etiology and severity in a cross-sectional cohort of people with SMI at a tertiary health service.
We recruited 255 people with SMI between August 2019 and March 2020. Liver disease data were derived from structured interview, medical records, biochemical and BBV serological analyses, and vibration-controlled transient elastography (VCTE). Steatosis was determined using a threshold of ≥ 248 db/m via the controlled attenuation parameter (CAP) on VCTE. Liver disease prevalence was assessed descriptively, and predictors of metabolic-dysfunction associated fatty liver disease (MAFLD) analyzed using linear regression and multivariable analysis. Best fit modeling of non-invasive screening tests for MAFLD was also assessed.
Valid VCTE was obtained for 252 (98.9%) participants. Median age was 40 years (IQR 31–49) with male predominance (65.9%). Hepatitis C Virus (HCV) seroprevalence was 14.7% (37/252), with four new viremic cases identified. Hepatic steatosis was diagnosed in 61.5% (155/252) of participants, with MAFLD criteria met in 59.9% (151/252) of cases. Clozapine and paliperidone were associated with hepatic steatosis (CAP + 23.3 db/m, p 0.013 and CAP + 25.5, p 0.037, respectively). Advanced liver disease, defined by LSM ≥ 8.2 kPa, was identified in 26 individuals (10.3%). MAFLD compared to no MAFLD was associated with more advanced liver disease (5.3 kPa, 4.3–6.5 versus 4.9 kPa, 3.9–5.6, p < 0.001).
Liver disease is common in people with SMI and should be screened for as part of standard physical health assessment.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Deidentified data will be provided to authorized academic partners upon written request.
Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry 2016;3(1):40–48
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511–2518
Carrier P, Debette-Gratien M, Girard M, Jacques J, Nubukpo P, Loustaud-Ratti V, et al. Liver illness and psychiatric patients. Hepat Mon 2016;16(12):e41564
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(1 Suppl):S47–S64
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84
Sokal J, Messias E, Dickerson FB, Kreyenbuhl J, Brown CH, Goldberg RW, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 2004;192(6):421–427
Piatt EE, Munetz MR, Ritter C. An examination of premature mortality among decedents with serious mental illness and those in the general population. Psychiatr Serv 2010;61(7):663–668
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017;66(6):1138–1153
Parabiaghi A, Bonetto C, Ruggeri M, Lasalvia A, Leese M. Severe and persistent mental illness: a useful definition for prioritizing community-based mental health service interventions. Soc Psychiatry Psychiatr Epidemiol 2006;41(6):457–463
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33
Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–209
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66(5):1022–1030
Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156(6):1717–1730
Australian Institute of Health and Welfare. Canberra: AIHW. 2019. https://www.aihw.gov.au/reports-data/australias-welfare/australias-welfare-snapshots. Accessed Aug 2020
Australian Bureau of Statistics [website]. Migration, Australia. 2019. https://www.abs.gov.au/statistics/people/population/migration-australia/2018-19. Accessed 12 July 2020
De Hert M, Cohen DA, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10(2):138–151
Farrell A, Magliano D, Shaw J, Thompson A, Croagh C, Ryan M, et al. Non-alcoholic fatty liver disease is a big problem in Australia: analysis from the AusDiab cohort [Abstract]. J Gastroenterol Hepatol 2020;35(Suppl. 1):34–104
Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxì A, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population. Liver Int 2018;38(11):2060–2068
Teeratorn N, Piyachaturawat P, Thanapirom K, Chaiteerakij R, Sonsiri K, Komolmit P, et al. Screening for non-alcoholic fatty liver disease in community setting: a cohort study using controlled attenuation parameter-transient elastography. JGH Open 2020;4(2):245–250
Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. Neuropsychiatr Dis Treat 2017;13:1493–1498
Mahady SE, Gale J, Macaskill P, Craig JC, George J, et al. Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: a cross-sectional study of 9,447 people. J Gastroenterol Hepatol 2017;32(1):169–176
Soliman HM, Wagih HM, Algaidi SA, Hafiz AH. Histological evaluation of the role of atypical antipsychotic drugs in inducing non-alcoholic fatty liver disease in adult male albino rats (light and electron microscopic study). Folia Biol (Praha) 2013;59(5):173–180
Weston-Green K, Babic I, De Santis M, Pan B, Montgomery MK, Mitchell T, et al. Disrupted sphingolipid metabolism following acute clozapine and olanzapine administration. J Biomed Sci 2018;25(1):40
Morlán-Coarasa MJ, Arias-Loste MT, de la Foz VO, Martínez-García O, Alonso-Martín C, Crespo J, et al. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology 2016;233(23–24):3947–3952
Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K, et al. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013;62(9):3232–3240
MacLachlan J, Thomas L, Cowie C. Hepatitis C Mapping Project: estimates of geographic diversity in chronic hepatitis C prevalence, diagnosis, monitoring and treatment—National Report 2016. Sydney: ASHM, 2018. https://ashm.org.au/products/product/Viral-Hepatitis-Mapping-Project-2017. Accessed May 2020
Australian Institute of Health and Welfare. Alcohol, tobacco & other drugs in Australia. 2020. https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia. Accessed 25 Sept 2020
Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40(9):2082–2089
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65(5):1557–1565
Conflict of interest
Michael Rudi Braude, Danny Con, John Lubel, Abhijit Bidwai, Hoang-Thy Nguyen, Shipra Sharmamiglani, David Clarke, Anouk Dev and William Sievert declares that they have nil financial or institution disclosures or conflicts of interest.
The study was approved by the Monash Health Human Research and Ethics Committee (RES-19-0000208A, HREC 52541) and was conducted in accordance with the Australian National Statement on Ethical Conduct in Human Research.
Consent to participate
Written consent was obtained from all recruited participants in accordance with the ethics-approved study protocol.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Braude, M.R., Con, D., Lubel, J. et al. Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools. Hepatol Int 15, 812–820 (2021). https://doi.org/10.1007/s12072-021-10195-6